References

Semaglutide for chronic kidney disease in type 2 diabetes

10.1056/nejmc2410532 · 2024 · External reference

Glucagon-like peptide-1 receptor agonist use and risks of hospitalization and mortality in patients with end-stage kidney disease

2026 · External reference

Association of glucagon-like peptide-1 receptor agonist vs dipeptidyl peptidase-4 inhibitor use with mortality among patients with type 2 diabetes and advanced chronic kidney disease

10.1001/jamanetworkopen.2022.1169 · 2022 · External reference

GLP-1 receptor agonist outcomes, safety, and body mass index change in a national cohort of patients on dialysis

10.2215/cjn.0000000750 · 2025 · External reference

Evaluating medication effects outside of clinical trials: new-user designs

10.1093/aje/kwg231 · 2003 · External reference

The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application

10.1007/s40471-015-0053-5 · 2015 · External reference

Global prevalence of protein-energy wasting in kidney disease: a meta-analysis of contemporary observational studies from the International Society of Renal Nutrition and Metabolism

10.1053/j.jrn.2018.08.006 · 2018 · External reference

Bariatric surgery and kidney health

10.1681/asn.2018020176 · 2018 · External reference

Obesity and metabolic health in CKD

10.2215/cjn.0000000704 · 2025 · External reference

Role of glucagon-like peptide-1 (GLP-1) receptor agonists in hypoglycemia

10.1177/11795514211051697 · 2021 · External reference